0056507f-a296-4148-bc9f-a831249c7973
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- ANGIOGENESIS+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
- TGF_BETA_SIGNALING+0.400
- APICAL_JUNCTION+0.300
- COMPLEMENT+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- OXIDATIVE_PHOSPHORYLATION-0.600
- PROTEIN_SECRETION-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- DNA_REPAIR-0.400
- FATTY_ACID_METABOLISM-0.400
- GLYCOLYSIS-0.400
- MTORC1_SIGNALING-0.400
- MYC_TARGETS_V1-0.400
- ADIPOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.934 |
| 2 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.922 |
| 3 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.920 |
| 4 | TCGA-60-2715-01A-01R-0851-07 | — | cohortSQ1 | 0.920 |
| 5 | TCGA-A2-A25A-01A-12R-A16F-07 | — | A | 0.918 |
| 6 | b8ac3f4d-393c-4d6b-a383-1347148760e5 | — | — | 0.916 |
| 7 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.913 |
| 8 | SRR2771286 | — | — | 0.912 |
| 9 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.912 |
| 10 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |